Therefore, GITR agonism presents a promising new strategy for cancer immunotherapy hence, there are multiple ongoing clinical trials investigating the effects of GITR agonism and its combination with ICI in different cancer types (193, 194). This evidence concerns the gene TNFRSF18 and cancer.